INCYTE CORP

(c) During the three months ended September 30, 2026, the following officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934 (the “Exchange Act”)) of our Company adopted or terminated, as described below, a prearranged trading plan relating to our common stock and intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act:

Steven Stein, our Executive Vice President, Chief Medical Officer and Head of Late-Stage Development, adopted a trading plan on August 7, 2026 providing for the sale of up to an aggregate of 282,480 shares of our common stock until August 7, 2027. On July 29, 2026, Dr. Stein terminated a trading plan which was previously adopted on March 16, 2026 and provided for the sale of up to an aggregate of 207,534 shares of our common stock until March 17, 2027. No sales were executed under the terminated trading plan.

Lee Heeson, our Executive Vice President and Head of Incyte International, adopted a trading plan on August 14, 2026 providing for the sale of up to an aggregate of 10,694 shares of our common stock until August 17, 2027.

Thomas Tray, our Vice President, Finance and Chief Accounting Officer, adopted a trading plan on July 31, 2026 providing for the sale of up to an aggregate of 4,128 shares of our common stock until July 31, 2027.

During the three months ended September 30, 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of our Company adopted orterminated any contract, instruction or written plan for the purchase or sale of our securities, whether or not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), other than as set forth above.